Employer-Sponsored GLP-1 Coverage Becomes Critical for Talent Retention and Acquisition, New 9amHealth Survey Finds
As the demand for GLP-1 weight loss medications such as Ozempic, Wegovy, and Zepbound continues to skyrocket, new survey ...
3 hot US stocks that have already doubled in 2025
These super high-flying US stocks have soared 222%, 122%, and 150%, respectively, in 2025. Let's take a look why.
Rolling Out18h
This weight loss drug reduces heart failure risk
A groundbreaking study shows how Zepbound, a popular weight loss medication, could become a key treatment for heart failure ...
Weight-loss drug Zepbound helped drive Ireland to $76 billion in goods exports to the U.S. last year—a bittersweet reminder of the challenges ahead
Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.
Ibj.com7h
Lebanon planning board OKs design for Lilly Medicine Foundry at LEAP District
Lebanon Plan Commission on Monday night unanimously approved a design plan for Eli Lilly and Co.’s $4.5 billion center for advanced manufacturing and drug development at the LEAP Research and ...
Zepbound for Weight Loss
The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...
3 Hot Stocks That Have Already Doubled in 2025
It may be early, but some blazing investments have already delivered wealth-altering gains in this young year.
Hims & Hers Q4 Preview: Is The Super Bowl Ad Worth $5B In Market Cap? (Rating Downgrade)
Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...